upfrontpsma trial: 177lu-psma-617 and docetaxel in mhnpc
Published 3 years ago • 209 plays • Length 2:46Download video MP4
Download video MP3
Similar videos
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
1:34
lu-psma-617 deployment and future of prostate cancer treatment
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
0:50
asco gu 2021 highlights: enfortumab vedotin, oral docetaxel and 177lu-psma-617
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
5:06
psmaddition: 177lu-psma-617 plus soc vs. soc alone in metastatic hormone-sensitive prostate cancer
-
3:41
177lu-psma-617 vs. cabazitaxel for mcrpc
-
1:09
psma imaging pre- and post-177lu-psma-617 treatment in mcrpc